相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study
Mar Riveiro-Barciela et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)
Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis
Michael Li et al.
HEPATOLOGY (2022)
Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors A Systematic Literature Review
Nilasha Ghosh et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2022)
Liver biopsy findings in patients on immune checkpoint inhibitors
Justine V. Cohen et al.
MODERN PATHOLOGY (2021)
Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers
Atsushi Yamamoto et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Liver Injury Caused by Green Tea Extract in PD-1-/- Mice: An Impaired Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury
Tiffany Cho et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2021)
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis
Cathrin L. C. Gudd et al.
JOURNAL OF HEPATOLOGY (2021)
Mechanisms of immune checkpoint inhibitor-mediated liver injury
Layla Shojaie et al.
ACTA PHARMACEUTICA SINICA B (2021)
Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis
Jianyang Fu et al.
FRONTIERS IN ONCOLOGY (2021)
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis
Prabhakaran Kumar et al.
SEMINARS IN CANCER BIOLOGY (2020)
Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors
Mar Riveiro-Barciela et al.
LIVER INTERNATIONAL (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Severe Refractory Checkpoint Inhibitor-Related Hepatitis Reversed With Anti-Thymocyte Globulin and n-Acetylcysteine
Douglas Motomura et al.
HEPATOLOGY (2020)
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
Arie Regev et al.
JOURNAL OF AUTOIMMUNITY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials
Joanne M. Mankor et al.
EBIOMEDICINE (2020)
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
Eleonora De Martin et al.
JHEP REPORTS (2020)
When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
Dimitrios C. Ziogas et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Hao Chi Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy
Irene Tsung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice
Timothy Affolter et al.
PLOS ONE (2019)
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Alice Tison et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Yousef R. Badran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
Naoto Okada et al.
CLINICAL THERAPEUTICS (2019)
Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors
Aurore Vozy et al.
EUROPEAN JOURNAL OF CANCER (2019)
Immunotherapy-related hepatitis: real-world experience from a tertiary centre
Vincent Cheung et al.
FRONTLINE GASTROENTEROLOGY (2019)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
Alexander T. Faje et al.
CANCER (2018)
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Katharina C. Kaehler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Francois-Xavier Danlos et al.
EUROPEAN JOURNAL OF CANCER (2018)
Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma
Tokuhiro Matsubara et al.
INTERNAL MEDICINE (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Eleonora De Martin et al.
JOURNAL OF HEPATOLOGY (2018)
Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?
Marie-Lea Gauci et al.
JOURNAL OF HEPATOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
Yoh Zen et al.
MODERN PATHOLOGY (2018)
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
Kerry Reynolds et al.
ONCOLOGIST (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mortality due to immunotherapy related hepatitis
Prachi Bhave et al.
JOURNAL OF HEPATOLOGY (2018)
TNFα sensitizes hepatocytes to FasL-induced apoptosis by NFκB-mediated Fas upregulation
Laura Faletti et al.
CELL DEATH & DISEASE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study
Lucia Parlati et al.
JOURNAL OF HEPATOLOGY (2018)
Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report
Helen M. McGuire et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M. H. Pollack et al.
ANNALS OF ONCOLOGY (2018)
Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury
F. Gelsomino et al.
ANNALS OF ONCOLOGY (2017)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data
Wenjun Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids
Mirjana Ziemer et al.
JOURNAL OF HEPATOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Possible Involvement of Liver Resident Macrophages (Kupffer Cells) in the Pathogenesis of Both Intrahepatic and Extrahepatic Inflammation
Yuki Kakinuma et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer
Zachary J. Brown et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
Gary Joseph Doherty et al.
ESMO OPEN (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Ipilimumab-associated Hepatitis Clinicopathologic Characterization in a Series of 11 Cases
Melanie Johncilla et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury
Alastair Mak et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2015)
The Role of CD8 T Cells in Amodiaquine-Induced Liver Injury in PD1-/- Mice Cotreated with Anti-CTLA-4
Alastair Mak et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2015)
Treatment of PD-1-/- Mice With Amodiaquine and Anti-CTLA4 Leads to Liver Injury Similar to Idiosyncratic Liver Injury in Patients
Imir G. Metushi et al.
HEPATOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kyung Won Kim et al.
INVESTIGATIONAL NEW DRUGS (2013)
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
Sebastian G. Bernardo et al.
MELANOMA RESEARCH (2013)
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
David E. Kleiner et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Liver Disorders in Inflammatory Bowel Disease
Victor Uko et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2012)
Regulation of hepatocyte fate by interferon-γ
Christopher J. Horras et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2011)
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Katarzyna D. Chmiel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Antigen-presenting cell function in the tolerogenic liver environment
Angus W. Thomson et al.
NATURE REVIEWS IMMUNOLOGY (2010)
The liver: an organ of the immune system?
Pascal Lapierre et al.
M S-MEDECINE SCIENCES (2007)
Pathogenesis of autoimmune hepatitis:: from break of tolerance to immune-mediated hepatocyte apoptosis
Pascal Lapierre et al.
TRANSLATIONAL RESEARCH (2007)
Local intrahepatic CD8+ T cell activation by a non-self-antigen results in full functional differentiation
Sherry A. Wuensch et al.
JOURNAL OF IMMUNOLOGY (2006)
Kupffer cell-dependent hepatitis occurs during influenza infection
NK Polakos et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
The liver as an immunological organ
V Racanelli et al.
HEPATOLOGY (2006)
Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: A role for alpha-4 integrin and vascular adhesion protein-1
CS Bonder et al.
IMMUNITY (2005)
Lymphocyte traffic through sinusoidal endothelial cells is regulated by hepatocytes
S Edwards et al.
HEPATOLOGY (2005)
Passive and active mechanisms trap activated CD8+ T cells in the liver
B John et al.
JOURNAL OF IMMUNOLOGY (2004)
The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity
DG Bowen et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
TNF-α controls intrahepatic T cell apoptosis and peripheral T cell numbers
DA Murray et al.
JOURNAL OF IMMUNOLOGY (2004)
Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells
PF Lalor et al.
JOURNAL OF IMMUNOLOGY (2002)
Epitope spreading in immunemediated diseases: Implications for immunotherapy
CL Vanderlugt et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Antigen-specific primary activation of CD8+ T cells within the liver
P Bertolino et al.
JOURNAL OF IMMUNOLOGY (2001)
Migration of activated CD8+ T lymphocytes to sites of viral infection does not require endothelial selectins
C Bartholdy et al.
BLOOD (2000)
The liver as a site of T-cell apoptosis: graveyard, or krilling field?
IN Crispe et al.
IMMUNOLOGICAL REVIEWS (2000)
分享论文
